IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application. Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, to read as follows:

Claims 1-48. (Cancelled)

49. (Currently amended) A dry powder composition suitable for inducing an immune response to anthrax in a subject when administered to a mucosal surface of the subject, comprising protective antigen (PA), chitosan, and MPL ~~and at least one mucosal adjuvant~~, wherein the immune response can ameliorate or prevent at least one symptom of anthrax disease.

Claims 50-53. (Cancelled)

54. (Previously presented) The composition of claim 49, wherein at least some of the PA is conjugated to a poly(γ-D-glutamic acid) (PGA) peptide.

55. (Previously Presented) The composition of claim 54, wherein the PGA peptide is synthetic.

56. (Previously Presented) The composition of claim 55, wherein the PGA peptide is a 10mer of poly(γ-D-glutamic acid).

Claims 57-60. (Cancelled)

61. (Previously presented) The dry powder composition of claim 49 in combination with one or more devices for administering one or more doses of said composition.

62. (Previously Presented) The dry powder composition of claim 61, wherein said one or more doses are unit doses.

63. (Previously Presented) The dry powder composition of claim 61, wherein the device is a single-use nasal administration device.

Claims 64-67. (Cancelled)

68. (Withdrawn) A method of inducing an immune response to anthrax in a subject, comprising administering to a mucosal surface of the subject an effective amount of the composition of claim 49.

69. (Withdrawn) The method of claim 68, wherein replication of anthrax in the subject is inhibited.

70. (Withdrawn) The method of claim 68, wherein anthrax exotoxin in the subject is neutralized.

71. (Withdrawn) The method of claim 68, wherein the immune response is a protective immune response.

72. (Withdrawn) The method of claim 68, wherein the mucosal surface is selected from the group consisting of a nasal mucosal surface and an oral mucosal surface.

73. (Withdrawn) The method of claim 68, wherein the subject has not been exposed to anthrax.

74. (Withdrawn) The method of claim 68, wherein the subject is infected with anthrax.

75. (Withdrawn) The method of claim 68, wherein the subject has been exposed to anthrax.

76. (Withdrawn) The method of claim 75, wherein the subject does not display visible signs of anorexia, lethargy and/or death as a result of exposure to anthrax.

77. (Withdrawn) The method of claim 76, wherein the subject does not display visible signs of anorexia, lethargy and/or death up to 2 weeks after anthrax exposure.

78. (Cancelled)

79. (Previously presented) The composition of claim 49 in combination with a mucosal administration device.